{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:48:20Z","timestamp":1789069700036,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jim.2020.112944","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T10:21:50Z","timestamp":1607854910000},"page":"112944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Monitoring Ravulizumab effect on complement assays"],"prefix":"10.1016","volume":"490","author":[{"given":"Maria A.V.","family":"Willrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Ladwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera R.","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2020.112944_bb0005","series-title":"FDA Documents Ed","article-title":"BLA 761108-S1 Multi-disciplinary review and evaluation: Ultomiris (ravulizumab-cwvz)","author":"Alexion Pharmaceuticals","year":"2020"},{"issue":"3","key":"10.1016\/j.jim.2020.112944_bb0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2018","journal-title":"Pediatr. Nephrol."},{"issue":"Supplement_1","key":"10.1016\/j.jim.2020.112944_bb0015","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2019-122421","article-title":"Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with Ravulizumab","volume":"134","author":"Cataland","year":"2019","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.jim.2020.112944_bb0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1208\/s12248-018-0266-x","article-title":"A gyrolab assay for the quantitation of free complement protein C5a in human plasma","volume":"20","author":"Dysinger","year":"2018","journal-title":"AAPS J."},{"issue":"6","key":"10.1016\/j.jim.2020.112944_bb0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.jim.2020.112944_bb0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s13361-016-1566-y","article-title":"Quantification of the IgG2\/4 kappa monoclonal therapeutic eculizumab from serum using Isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry","volume":"28","author":"Ladwig","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"23","key":"10.1016\/j.jim.2020.112944_bb0035","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2020.112944_bb0040","series-title":"XXVIII Congress of the International Society on Thrombosis and Haemostasis. Virtual ISTH 2020","article-title":"Personalized dosing of eculizumab using C5 functional activity and eculizumab level in complement-mediated thrombotic microangiopathy: A safe and cost-saving approach","author":"Sridharan","year":"2020"},{"key":"10.1016\/j.jim.2020.112944_bb0045","first-page":"10","article-title":"Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria","author":"Stern","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"2","key":"10.1016\/j.jim.2020.112944_bb0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jim.2020.112944_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","article-title":"The impact of eculizumab on routine complement assays","volume":"460","author":"Willrich","year":"2018","journal-title":"J. Immunol. Methods"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175920302386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175920302386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:27:00Z","timestamp":1762205220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175920302386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":11,"alternative-id":["S0022175920302386"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2020.112944","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring Ravulizumab effect on complement assays","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2020.112944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112944"}}